Extended Data Fig. 8: Efficacy of CAR T-cell treatment on patients-related outcomes, autoantibody and vaccination-related antibody levels.

Effects of treatment with chimeric antigen receptor (CAR) T-cells on (a) patient-based global disease activity measured by visual analogue scale (VAS; N = 24), (b) physician-based global disease activity measured by visual analogue scale (VAS; N = 24), (c) physical function measured by health assessment questionnaire (HAQ; N = 24) and (d) fatigue measured by Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT; N = 24); (e) Changes in patient-related outcomes between baseline and 24-week follow-up. Visual Analogue Scale (VAS) for Patient-rated Global Disease Activity (PGA) and Physician-rated Global Disease Activity (PGA); Health Assessment Questionaire (HAQ); Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT). P-values are based on Wilcoxon signed rank test. (f) Effects on autoantibodies against nucleosomes (N = 8; in SLE), histones (N = 6; in SLE), SCL70 (N = 8; in SSc), SS-A/Ro60 (N = 6, in all), SS-A/Ro52 (N = 8; in all). (g) Effects on vaccination-related antibodies against measles, mumps, rubella, varicella zoster virus (VZV), Epstein Barr Virus (EBV), tetanus, and severe acute respiratory distress syndrome coronavirus- 2 (SARS-CoV-2) (N = 24).